Evidence map›Paper›PMID 25013471›Full record

ArticleOncology letters2014

Differential levels of L-homocysteic acid and lysophosphatidylcholine (16:0) in sera of patients with ovarian cancer.

Seung Cheol Kim, Min Kyung Kim, Yun Hwan Kim, Sun-A Ahn, Kyung-Hee Kim, Kun Kim, Won Ki Kim, Jun Hwa Lee, Jae Youl Cho, Byong Chul Yoo

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Characterization of Lipid Alterations by OncogenicOmics : a journal of integrative biology · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Seung Cheol KimDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ewha Woman's University Mokdong Hospital, Ewha Woman's University School of Medicine, Seoul 158-710, Republic of Korea.
Min Kyung KimColorectal Cancer Branch, Research Institute, National Cancer Center, Gyeonggi 410-769, Republic of Korea.
Yun Hwan KimDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ewha Woman's University Mokdong Hospital, Ewha Woman's University School of Medicine, Seoul 158-710, Republic of Korea.
Sun-A AhnColorectal Cancer Branch, Research Institute, National Cancer Center, Gyeonggi 410-769, Republic of Korea.
Kyung-Hee KimColorectal Cancer Branch, Research Institute, National Cancer Center, Gyeonggi 410-769, Republic of Korea.
Kun KimColorectal Cancer Branch, Research Institute, National Cancer Center, Gyeonggi 410-769, Republic of Korea.
Won Ki KimColorectal Cancer Branch, Research Institute, National Cancer Center, Gyeonggi 410-769, Republic of Korea.
Jun Hwa LeeDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ewha Woman's University Mokdong Hospital, Ewha Woman's University School of Medicine, Seoul 158-710, Republic of Korea.
Jae Youl ChoDepartment of Genetic Engineering, Sungkyunkwan University, Gyeonggi 440-746, Republic of Korea.
Byong Chul YooColorectal Cancer Branch, Research Institute, National Cancer Center, Gyeonggi 410-769, Republic of Korea.
National Cancer Center · KREwha Womans University · KRSungkyunkwan University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OVC) is one of the most difficult types of cancer to detect in the early stages of its development. There have been numerous attempts to identify a biomarker for OVC; however, an accurate diagnostic marker has yet to be identified. The present study profiled OVC candidate metabolites from the serum to identify potential diagnostic markers for OVC. Data regarding low-mass ions (LMIs) in the serum were obtained using matrix-assisted laser desorption/ionization (MALDI)-time-of-flight analysis. MALDI-mass spectrometry (MS) analysis of each serum sample was repeated six times in order to reduce the likelihood of experimental errors. The intensity of the LMI mass peaks were normalized using total peak area sums. The normalized intensity of LMI was used in principal component analysis-discriminant analysis to differentiate between 142 patients with OVC and 100 healthy control participants. Liquid chromatography-MS/MS was used to identify the selected LMIs. Extracted ion chromatogram analysis was used to measure the relative quantity of candidate metabolites from the LMI mass peak areas. The concentration of common metabolites in the serum was determined using ELISA. The top 20 LMI mass peaks with a weigh factor over 0.05 were selected to distinguish between the patients with OVC and the controls. Among the LMIs, two with 184.05 and 496.30 m/z were identified as L-homocysteic acid (HCA) and lysophosphatidylcholine (LPC) (16:0), respectively. The relative quantity of LPC (16:0) was found to be decreased in the OVC serum (P=0.05), while the quantity of HCA was observed to be significantly higher in the OVC serum (P<0.001). HCA was not detected in 59 cases out of the 63 control participants; however, the majority of the cases of OVC (16/25) exhibited significantly higher quantities of HCA. When the cutoff was 10 nmol/ml, the sensitivity and specificity of HCA were 64.0 and 96.9%, respectively. The level of LPC (16:0) was significantly correlated with tumor grade (P=0.045). HCA and LPC (16:0) showed correlation with stage and tumor histology, but the limited sample size resulted in a lack of statistical significance. The findings of the present study suggest that HCA may have potential to be a biomarker for OVC. The stratified screening including LPC (16:0) did not significantly increase the power for OVC screening; however, the present study showed that profiling LMIs in serum may be useful for identifying candidate metabolites for OVC screening.

Indexed as

biomarkercancer screeningL-homocysteic acidlysophosphatidylcholine (16:0)ovarian cancer

Identifiers

PMID25013471
PMCPMC4081284
OpenAlexW2082730398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.